| Acquired by | Roche Holding |
| Price | $56.5M |
| Date | 4/07 |
| Category | BioTech |
| Employees |
THP is an emerging biotechnology company focused on research in the field of human antibody technologies. THP has developed a unique transgenic mammalian platform to create human antibodies. The technology will enable the generation of both monoclonal and polyclonal antibody therapeutics with enhanced efficacy.
